Canopy Growth Corporation (TSX:WEED)
Canada · Delayed Price · Currency is CAD | Market Cap | 552.19M +37.4% |
| Revenue (ttm) | 278.39M +0.6% |
| Net Income | -326.58M |
| EPS | -1.36 |
| Shares Out | 380.82M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 2,285,044 |
| Open | 1.440 |
| Previous Close | 1.440 |
| Day's Range | 1.405 - 1.510 |
| 52-Week Range | 1.180 - 3.280 |
| Beta | 2.41 |
| Analysts | Hold |
| Price Target | 2.38 (+64.14%) |
| Earnings Date | Jun 15, 2026 |
About Canopy Growth
Canopy Growth Corporation, together with its subsidiaries, engages in the production, distribution, and sale of cannabis, hemp, and cannabis-related products in Canada, Germany, and Australia. It operates through four segments: Canada Cannabis, International Markets Cannabis, and Storz & Bickel, and This Works. The company offers dried flower and pre-rolled joints; extracts and concentrates, such as softgel capsules; cannabis edibles, including gummies; cannabis vapes; and oils, beverages, concentrates. It sells its products under the Tweed, 7A... [Read more]
Full Company ProfileFinancial Performance
In fiscal year 2025, Canopy Growth's revenue was 269.00 million, a decrease of -9.47% compared to the previous year's 297.15 million. Losses were -598.12 million, -9.00% less than in 2024.
Financial StatementsAnalyst Summary
According to 7 analysts, the average rating for WEED stock is "Hold." The 12-month stock price target is $2.38, which is an increase of 64.14% from the latest price.
News
Canopy Growth Announces Claybourne's Frosted Flyers Wins ‘Best Infused Pre-Roll' at 2026 Grow Up Awards
SMITHS FALLS, Ontario--(BUSINESS WIRE)--Canopy Growth Announces Claybourne's Frosted Flyers Wins ‘Best Infused Pre-Roll' at 2026 Grow Up Awards.
Canopy Growth Just Made a Big Acquisition: Game-Changer -- or Another Misstep?
It will likely be more of the same from here on out for this cannabis player.
3 Canadian Marijuana Stocks That Could Help You Make Money
Those who have been investing in marijuana stocks over the years have seen many changes. If you have been investing and trading since just before the pandemic, then you know how exciting the sector ca...
Canopy Growth Still Looks Broken -- But These 3 Numbers Suggest a Turnaround May Be Starting
Adjusted EBITDA losses have fallen dramatically from prior years. Medical cannabis revenue grew 15% year over year.
The Market Overreacted to the DEA's Marijuana Rescheduling -- Here's What It Means for Canopy Growth Stock Now
Medical marijuana was moved to the DEA's Schedule III from Schedule I. This confers some accounting advantages, at best, and the company can't even capitalize on them yet.
Canopy Growth (CGC) Relaunches Tweed Brand in Germany
Canopy Growth (CGC) Relaunches Tweed Brand in Germany
Canopy Growth relaunches the Tweed brand in the German medical market
Canopy Growth (CGC) announced the relaunch of the Tweed brand in the German medical market, alongside the introduction of three cannabis strains developed by MTL Cannabis, a wholly-owned subsidiary of...
Canopy Growth Relaunches Tweed Brand in Germany with New MTL Cannabis Strain Lineup, Marking First International Release following Acquisition
SMITH FALLS, Ontario--(BUSINESS WIRE)--Canopy Growth Corporation (“Canopy Growth” or the “Company”) (TSX: WEED) (Nasdaq: CGC) today announced the relaunch of the Tweed brand in the German medical mark...
Top Canadian Marijuana Stocks for Your Watchlist Before June 2026
The Canadian cannabis sector continues showing signs of long-term potential heading into June 2026. Several companies are expanding globally while improving operational efficiency. In addition, many c...
Canopy Growth Is Restating Two Years of Financials Before June 15 Earnings -- Here's What CGC Investors Need to Know Right Now
Canopy Growth is an important player in the marijuana sector. The stock is trading in penny-stock territory.
Should You Buy CGC Stock After Marijuana Reclassification?
Canopy Growth gains attention as marijuana reclassification boosts cannabis sentiment, but margin pressure and execution risks persist.
Canopy Growth's Stock Just Dropped -- Here's Why I'm Still Not Buying
The company has struggled to improve its business -- and especially to earn a profit. It also has a habit of making dilutive secondary share issues.
Canopy Growth Provides Update on Financial Reporting and Announces Fourth Quarter and Fiscal Year 2026 Financial Results to be Presented on June 15, 2026
SMITHS FALLS, Ontario--(BUSINESS WIRE)--Canopy Growth Corporation (“Canopy Growth” or the “Company”) (TSX: WEED) (Nasdaq: CGC) expects to release its financial results for the quarter and fiscal year ...
Is Canopy Growth Stock Finally Setting Up for a Real Turnaround?
The cannabis company has reduced debt and stacked up cash, but profitability remains elusive.
Canadian Marijuana Stocks Showing Strong Momentum in May
Canadian cannabis stocks remain active in May 2026. Investors continue watching the sector for growth opportunities and reform catalysts. In addition, many traders expect future federal progress in th...
Canopy Growth Is One of the Market's Most Polarizing Stocks: 3 Scenarios for the Next 12 Months
Investors are no longer buying a hypergrowth cannabis stock. They're betting on a turnaround story.
Canopy Growth, Spectrum expand Minor Cannabinoid softgel lineup
Canopy Growth (CGC) Corporation and Spectrum Therapeutics announced an expansion of its Minor Cannabinoid softgel lineup, introducing new 30 and 90-pack formats and additional dosing options across it...
Canopy Growth and Spectrum Therapeutics Expand Medical Portfolio with New 30 and 90-Pack Softgels and Enhanced Dosing Options
SMITHS FALLS, Ontario--(BUSINESS WIRE)--Canopy Growth Corporation (“Canopy Growth” or the “Company”) (TSX: WEED) (Nasdaq: CGC) and Spectrum Therapeutics today announced an expansion of its Minor Canna...
3 Canadian Marijuana Stocks That Could Benefit From U.S. Reform
The Canadian cannabis sector continues to evolve as investors look for the next major catalyst. Recently, optimism has increased around potential U.S. cannabis reform. As a result, many Canadian compa...
Canopy Growth Stock Is Jumping. Is It Overdue for a Much Bigger Rally?
The pot stock is up over 30% in just the past month.
Canopy Growth Is Rallying Again. But Is It a Dead Cat Bounce?
Canopy Growth is a penny stock, so small price movements can lead to huge percentage changes. The marijuana company recently bought another company, extending its reach in medical marijuana.
'GIANT STEP FORWARD': Reclassification of medical cannabis lauded
Trulieve founder and CEO Kim Rivers discusses the impact of Trump's administration reclassifying state-licensed medical cannabis from Schedule 1 to Schedule 3 on 'Varney & Co.' 00:00 Introduction & Re...
Akanda Shares Soar As Cannabis Stocks Rise On US Policy Change
Akanda Corp. (NASDAQ: AKAN) shares continued to surge today after U.S. regulators moved to reclassify certain marijuana products, fueling a broader rally in cannabis stocks. • Akanda stock is chargin...
'Big Business Opportunity': Cannabis CEO Celebrates DOJ Easing Regulations On Medical Marijuana
The Trump administration reclassified medical marijuana as a less dangerous drug on Thursday. FDA-approved and state-licensed medical marijuana was rescheduled from a Schedule I drug to the less stric...
The cannabis rescheduling is causing celebration — and confusion — as marijuana stocks sell off
Marijuana stocks sold off Thursday, after acting U.S. Attorney General Todd Blanche signed an order rescheduling Food and Drug Administration-approved and state-licensed medical cannabis products as a...